How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery
In this article:
BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.
Advertisement
BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.